Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022160017 - SARS-COV-2 VACCINE ANTIGENS

Publication Number WO/2022/160017
Publication Date 04.08.2022
International Application No. PCT/AU2022/050050
International Filing Date 01.02.2022
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61K 39/295 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/005 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Applicants
  • GRIFFITH UNIVERSITY [AU]/[AU]
  • GOLD COAST HOSPITAL AND HEALTH SERVICE [AU]/[AU]
Inventors
  • GOOD, Michael
  • PANDEY, Manisha
  • GERRARD, John Gregory
Agents
  • FB RICE
Priority Data
202190021201.02.2021AU
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SARS-COV-2 VACCINE ANTIGENS
(FR) ANTIGÈNES DE VACCIN CONTE LE SARS-COV-2
Abstract
(EN) The present disclosure provides immunogenic compositions and methods of inducing an immune response and/or preventing, treating or ameliorating an infection, disease or condition associated with SARS-CoV-2 in a subject with such immunogenic compositions.
(FR) La présente divulgation concerne des compositions immunogènes et des méthodes d'induction d'une réponse immunitaire et/ou de prévention, de traitement ou d'atténuation d'une infection, d'une maladie ou d'un état pathologique associé au SARS-CoV-2 chez un patient avec de telles compositions immunogènes.
Latest bibliographic data on file with the International Bureau